Where does the new drug paramivir illuminate?

It is reported that the National Health and Family Planning Commission announced on April 7 that people were infected with the H7N9 bird flu epidemic. From April 17th to April 7th on April 7th, 2 new confirmed cases of H7N9 bird flu infection were reported nationwide. As of now, a total of 20 confirmed cases have been reported across the country, including 6 deaths.

There is also news circulating that H7N9 may be mutated and cause people to feel guilty. It is worth celebrating that the State Food and Drug Administration recently approved the new anti-influenza paramalavir sodium chloride injection.

It is reported that Peramivir is a neuraminidase inhibitor. According to the World Health Organization, H7N9 is a subtype of Influenza A virus. Preliminary results show that a neuraminidase inhibitor may work on the virus. China is one of the few countries that has approved the listing of peramivir, including the United States, Japan, and South Korea.

According to public information, Guangzhou Nanxin Pharmaceutical Co., Ltd. is the only company in the country that currently produces Peramivir Sodium Chloride Injection. Baiyunshan A holds a 13% stake in Guangzhou Nanxin. However, analysts believe that these conditions alone are not enough to form a major advantage, and that Baiyun Mountain A is in the suspension period of reorganization, leading market speculators to speculate. It remains to be seen which of the unlisted listed companies Paramivir will light up.